R. Ojha

Intact and Degenerate Diguanylate Cyclases regulate Shigella Cyclic di-GMP

This study examines the role of intact and degenerate DGCs in Shigella c-di-GMP synthesis and pathogenesis, finding that some degenerate DGCs still produce c-di-GMP despite mutations.

Complete Protection from SARS-CoV-2 Lung Infection in Mice Through Combined Intranasal Delivery of PIKfyve Kinase and TMPRSS2 Protease Inhibitors

This study shows that combining PIKfyve and TMPRSS2 inhibitors intranasally protects mice from SARS-CoV-2 lung infection and reduces cell death.

Alternative cell entry mechanisms for SARS-CoV-2 and multiple animal viruses

This study identifies alternative cell entry mechanisms for SARS-CoV-2 and other viruses, showing some rely on dynamin while others use actin-dependent pathways.

Inhibition of host N-myristoylation compromises the infectivity of SARS-CoV-2 due to Golgi-bypassing egress from lysosomes and endoplasmic reticulum

This study shows that inhibiting host N-myristoylation reduces SARS-CoV-2 infectivity by impairing viral envelope protein maturation and causing Golgi-bypassing egress.

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein

SARS-CoV-2 requires acidic pH to infect cells

This study shows SARS-CoV-2 requires acidic pH for membrane fusion and genome release, even after proteolytic cleavage by furin or TMPRSS2.

Loss-of-function mutations in novel triacylglycerol lipase genes are associated with low rancidity in pearl millet flour

Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease

This study finds that combining apilimod and camostat mesylate or nafamostat mesylate significantly enhances inhibition of SARS-CoV-2 infection in vitro.

Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation

The paper identifies two compounds that inhibit SARS-CoV-2 infection and syncytia formation through computational prioritization and in vitro testing.